| FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. | |
| | |
MedLine Citation:
|
PMID: 20460491 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Despite the progress that has been made in the treatment of mantle cell lymphoma (MCL), all patients invariably relapse with the currently available therapies. Because of the absence of curative therapy for MCL, we explored FTY720 as a novel agent against MCL. EXPERIMENTAL DESIGN: The cytotoxic effect of FTY720 in primary MCL tumor cells and cell lines were evaluated in vitro. The effects of FTY720 on caspase activation, generation of reactive oxygen species, and modulation of Cyclin D1 and Akt, which are implied in the pathogenesis of MCL, were investigated. The in vivo efficacy of FTY720 was evaluated in a Jeko-severe combined immunodeficient xenograft model of human MCL. RESULTS: FTY720 mediated time- and dose-dependent cytotoxicity in primary MCL tumor cells and MCL cell lines in vitro. FTY720-induced cytotoxicity occured independent of caspase activation but dependent on the generation of ROS in MCL. In addition, FTY720 treatment resulted in the time-dependent downmodulation of Cyclin D1 and accumulation of cells in G(0)-G(1) and G(2)-M phases of the cell cycle with concomitant decrease in S-phase entry. Furthermore, concentrations of FTY720 that induced cytotoxicity led to decreased phospho-Akt in primary MCL cells and cell lines. Most importantly, the in vivo therapeutic activity of FTY720 was shown in severe combined immunodeficient mice engrafted with the Jeko MCL cell line. CONCLUSIONS: These results provide the first evidence for a potential use of FTY720 in targeting key pathways that are operable in the pathogenesis of MCL and warrant further investigation of FTY720 in clinical trials to treat patients with MCL. |
| | |
Authors:
|
Qing Liu; Lapo Alinari; Ching-Shih Chen; Fengting Yan; James T Dalton; Rosa Lapalombella; Xiaoli Zhang; Rajeswaran Mani; Teresa Lin; John C Byrd; Robert A Baiocchi; Natarajan Muthusamy |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-05-11 |
Journal Detail:
|
Title: Clinical cancer research : an official journal of the American Association for Cancer Research Volume: 16 ISSN: 1078-0432 ISO Abbreviation: Clin. Cancer Res. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-06-16 Completed Date: 2010-08-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9502500 Medline TA: Clin Cancer Res Country: United States |
Other Details:
|
Languages: eng Pagination: 3182-92 Citation Subset: IM |
Copyright Information:
|
(c) 2010 AACR. |
Affiliation:
|
Division of Pharmaceutics, College of Pharmacy, the Ohio State University, Columbus, Ohio 43210, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Agents / therapeutic use* Apoptosis Cell Cycle Cell Line, Tumor Cyclin D1 / metabolism* Female Humans Lymphoma, Mantle-Cell / drug therapy* Mice Mice, SCID Propylene Glycols / therapeutic use* Proto-Oncogene Proteins c-akt / metabolism* Reactive Oxygen Species / metabolism Sphingosine / analogs & derivatives*, therapeutic use Xenograft Model Antitumor Assays |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Propylene Glycols; 0/Reactive Oxygen Species; 123-78-4/Sphingosine; 136601-57-5/Cyclin D1; 162359-55-9/fingolimod; EC 2.7.11.1/Proto-Oncogene Proteins c-akt |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer.
Next Document: Epigenetic Markers in Rectal Cancer.